{
 "drug": "Methotrexate Sodium Injection",
 "asOf": "2026-08-25",
 "status": "in-shortage",
 "since": "03/13/2023",
 "dayN": 1261,
 "cat": "Rheumatology",
 "companies": [
  "Hikma Pharmaceuticals USA, Inc.",
  "Teva Pharmaceuticals USA, Inc.",
  "Hospira, Inc., a Pfizer Company",
  "Fresenius Kabi USA, LLC",
  "Accord Healthcare Inc."
 ],
 "reasons": [
  "Other",
  "Demand increase for the drug"
 ],
 "records": [
  {
   "update_type": "Reverified",
   "initial_posting_date": "03/13/2023",
   "package_ndc": "0143-9519-10",
   "generic_name": "Methotrexate Sodium Injection",
   "contact_info": "800-631-2174",
   "availability": "Available",
   "related_info": "Additional lots are scheduled to be manufactured.  Product will be made available as it is released.",
   "openfda": {
    "application_number": [
     "ANDA089340"
    ],
    "brand_name": [
     "METHOTREXATE"
    ],
    "generic_name": [
     "METHOTREXATE"
    ],
    "manufacturer_name": [
     "Hikma Pharmaceuticals USA Inc."
    ],
    "product_ndc": [
     "0143-9519",
     "0143-9518",
     "0143-9517",
     "0143-9516"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRA-ARTERIAL",
     "INTRAMUSCULAR",
     "INTRATHECAL",
     "INTRAVENOUS"
    ],
    "substance_name": [
     "METHOTREXATE"
    ],
    "rxcui": [
     "1655959",
     "1655960",
     "1655967",
     "1655968"
    ],
    "spl_id": [
     "3046ff78-3565-46d1-a88b-283e5ff6e7c3"
    ],
    "spl_set_id": [
     "3989d30d-56e5-4e8d-9379-c30fecc894f2"
    ],
    "package_ndc": [
     "0143-9519-10",
     "0143-9518-01",
     "0143-9517-01",
     "0143-9516-01"
    ],
    "nui": [
     "N0000175584",
     "N0000000111"
    ],
    "pharm_class_epc": [
     "Folate Analog Metabolic Inhibitor [EPC]"
    ],
    "pharm_class_moa": [
     "Folic Acid Metabolism Inhibitors [MoA]"
    ],
    "unii": [
     "YL5FZ2Y5U1"
    ]
   },
   "update_date": "08/13/2026",
   "therapeutic_category": [
    "Rheumatology",
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)",
   "company_name": "Hikma Pharmaceuticals USA, Inc.",
   "status": "Current"
  },
  {
   "update_type": "Revised",
   "initial_posting_date": "03/13/2023",
   "package_ndc": "0703-3671-01",
   "generic_name": "Methotrexate Sodium Injection",
   "contact_info": "800-545-8800",
   "availability": "Unavailable",
   "related_info": "Estimated recovery: October 2026",
   "openfda": {
    "application_number": [
     "ANDA040843"
    ],
    "brand_name": [
     "METHOTREXATE"
    ],
    "generic_name": [
     "METHOTREXATE"
    ],
    "manufacturer_name": [
     "Teva Parenteral Medicines, Inc."
    ],
    "product_ndc": [
     "0703-3671",
     "0703-3675",
     "0703-3678"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRA-ARTERIAL",
     "INTRAMUSCULAR",
     "INTRATHECAL",
     "INTRAVENOUS"
    ],
    "substance_name": [
     "METHOTREXATE SODIUM"
    ],
    "rxcui": [
     "1655956",
     "1655959",
     "1655960"
    ],
    "spl_id": [
     "e81074cc-12b4-4ac9-a5bb-749188989b2c"
    ],
    "spl_set_id": [
     "346ec9ce-dc98-4a55-b55e-d3af11f2d703"
    ],
    "package_ndc": [
     "0703-3671-01",
     "0703-3675-01",
     "0703-3678-01"
    ],
    "unii": [
     "3IG1E710ZN"
    ]
   },
   "update_date": "08/17/2026",
   "therapeutic_category": [
    "Rheumatology",
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)",
   "company_name": "Teva Pharmaceuticals USA, Inc.",
   "shortage_reason": "Other",
   "status": "Current"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "03/13/2023",
   "package_ndc": "61703-350-10",
   "generic_name": "Methotrexate Sodium Injection",
   "contact_info": "844-646-4398",
   "availability": "Available",
   "openfda": {
    "application_number": [
     "NDA011719"
    ],
    "brand_name": [
     "METHOTREXATE"
    ],
    "generic_name": [
     "METHOTREXATE"
    ],
    "manufacturer_name": [
     "Hospira, Inc."
    ],
    "product_ndc": [
     "61703-350",
     "61703-408"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAMUSCULAR",
     "INTRAVENOUS",
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "METHOTREXATE SODIUM"
    ],
    "rxcui": [
     "1655956",
     "1946772"
    ],
    "spl_id": [
     "95b8b8da-da4e-4bba-9038-3cf65f3d5c1a",
     "37b3e76b-ac3d-4f93-adf1-91f52f676b8a"
    ],
    "spl_set_id": [
     "0d63ba29-b692-41b4-87e8-351265c8273f",
     "0e30eaef-5a09-4104-8a11-c32933eadeab"
    ],
    "package_ndc": [
     "61703-350-37",
     "61703-350-38",
     "61703-408-41",
     "61703-350-09",
     "61703-350-10",
     "61703-408-25"
    ],
    "unii": [
     "3IG1E710ZN"
    ]
   },
   "update_date": "08/07/2026",
   "therapeutic_category": [
    "Rheumatology",
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Methotrexate Sodium, Injection, 50 mg/2 mL  (25 mg/mL) (NDC 61703-350-10)",
   "company_name": "Hospira, Inc., a Pfizer Company",
   "status": "Current"
  },
  {
   "update_type": "Revised",
   "initial_posting_date": "03/13/2023",
   "package_ndc": "0703-3678-01",
   "generic_name": "Methotrexate Sodium Injection",
   "contact_info": "800-545-8800",
   "availability": "Unavailable",
   "related_info": "Estimated recovery: October 2026",
   "openfda": {
    "application_number": [
     "ANDA040843"
    ],
    "brand_name": [
     "METHOTREXATE"
    ],
    "generic_name": [
     "METHOTREXATE"
    ],
    "manufacturer_name": [
     "Teva Parenteral Medicines, Inc."
    ],
    "product_ndc": [
     "0703-3678",
     "0703-3671",
     "0703-3675"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRA-ARTERIAL",
     "INTRAMUSCULAR",
     "INTRATHECAL",
     "INTRAVENOUS"
    ],
    "substance_name": [
     "METHOTREXATE SODIUM"
    ],
    "rxcui": [
     "1655956",
     "1655959",
     "1655960"
    ],
    "spl_id": [
     "e81074cc-12b4-4ac9-a5bb-749188989b2c"
    ],
    "spl_set_id": [
     "346ec9ce-dc98-4a55-b55e-d3af11f2d703"
    ],
    "package_ndc": [
     "0703-3671-01",
     "0703-3675-01",
     "0703-3678-01"
    ],
    "unii": [
     "3IG1E710ZN"
    ]
   },
   "update_date": "08/17/2026",
   "therapeutic_category": [
    "Rheumatology",
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)",
   "company_name": "Teva Pharmaceuticals USA, Inc.",
   "shortage_reason": "Other",
   "status": "Current"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "03/13/2023",
   "package_ndc": "63323-122-50",
   "generic_name": "Methotrexate Sodium Injection",
   "contact_info": "888-386-1300",
   "availability": "Available",
   "related_info": "Check wholesaler for inventory",
   "openfda": {
    "application_number": [
     "ANDA040266"
    ],
    "brand_name": [
     "METHOTREXATE"
    ],
    "generic_name": [
     "METHOTREXATE SODIUM"
    ],
    "manufacturer_name": [
     "Fresenius Kabi USA, LLC"
    ],
    "product_ndc": [
     "63323-122"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRA-ARTERIAL",
     "INTRAMUSCULAR",
     "INTRATHECAL",
     "INTRAVENOUS"
    ],
    "substance_name": [
     "METHOTREXATE SODIUM"
    ],
    "rxcui": [
     "311625"
    ],
    "spl_id": [
     "3d21237a-ef53-4592-bf06-0c739696203d"
    ],
    "spl_set_id": [
     "ec476b11-0b3c-4139-b1eb-a3daa76bc271"
    ],
    "package_ndc": [
     "63323-122-50"
    ],
    "unii": [
     "3IG1E710ZN"
    ]
   },
   "update_date": "08/04/2026",
   "therapeutic_category": [
    "Rheumatology",
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)",
   "company_name": "Fresenius Kabi USA, LLC",
   "status": "Current"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "03/13/2023",
   "package_ndc": "61703-408-41",
   "generic_name": "Methotrexate Sodium Injection",
   "contact_info": "844-646-4398",
   "availability": "Available",
   "openfda": {
    "application_number": [
     "NDA011719"
    ],
    "brand_name": [
     "METHOTREXATE"
    ],
    "generic_name": [
     "METHOTREXATE"
    ],
    "manufacturer_name": [
     "Hospira, Inc."
    ],
    "product_ndc": [
     "61703-408",
     "61703-350"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAMUSCULAR",
     "INTRATHECAL",
     "INTRAVENOUS",
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "METHOTREXATE SODIUM"
    ],
    "rxcui": [
     "1655956",
     "1946772"
    ],
    "spl_id": [
     "95b8b8da-da4e-4bba-9038-3cf65f3d5c1a",
     "37b3e76b-ac3d-4f93-adf1-91f52f676b8a"
    ],
    "spl_set_id": [
     "0d63ba29-b692-41b4-87e8-351265c8273f",
     "0e30eaef-5a09-4104-8a11-c32933eadeab"
    ],
    "package_ndc": [
     "61703-350-37",
     "61703-350-38",
     "61703-408-41",
     "61703-350-09",
     "61703-350-10",
     "61703-408-25"
    ],
    "unii": [
     "3IG1E710ZN"
    ]
   },
   "update_date": "08/07/2026",
   "therapeutic_category": [
    "Rheumatology",
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)",
   "company_name": "Hospira, Inc., a Pfizer Company",
   "status": "Current"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "03/13/2023",
   "package_ndc": "16729-277-30",
   "generic_name": "Methotrexate Sodium Injection",
   "contact_info": "866-941-7875, option 2",
   "availability": "Available",
   "openfda": {
    "application_number": [
     "ANDA040716"
    ],
    "brand_name": [
     "METHOTREXATE"
    ],
    "generic_name": [
     "METHOTREXATE"
    ],
    "manufacturer_name": [
     "Accord Healthcare, Inc."
    ],
    "product_ndc": [
     "16729-277"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRA-ARTERIAL",
     "INTRAMUSCULAR",
     "INTRATHECAL",
     "INTRAVENOUS"
    ],
    "substance_name": [
     "METHOTREXATE"
    ],
    "rxcui": [
     "1655956",
     "1655959",
     "1655960"
    ],
    "spl_id": [
     "2bae3cfe-7aa0-c14c-e063-6294a90a19f4"
    ],
    "spl_set_id": [
     "dd035a9f-cd40-4314-b9d8-2294b8a924e2"
    ],
    "package_ndc": [
     "16729-277-30",
     "16729-277-03",
     "16729-277-35"
    ],
    "nui": [
     "N0000175584",
     "N0000000111"
    ],
    "pharm_class_epc": [
     "Folate Analog Metabolic Inhibitor [EPC]"
    ],
    "pharm_class_moa": [
     "Folic Acid Metabolism Inhibitors [MoA]"
    ],
    "unii": [
     "YL5FZ2Y5U1"
    ]
   },
   "update_date": "08/17/2026",
   "therapeutic_category": [
    "Rheumatology",
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)",
   "company_name": "Accord Healthcare Inc.",
   "status": "Current"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "03/13/2023",
   "package_ndc": "61703-350-38",
   "generic_name": "Methotrexate Sodium Injection",
   "contact_info": "844-646-4398",
   "availability": "Available",
   "openfda": {
    "application_number": [
     "NDA011719"
    ],
    "brand_name": [
     "METHOTREXATE"
    ],
    "generic_name": [
     "METHOTREXATE"
    ],
    "manufacturer_name": [
     "Hospira, Inc."
    ],
    "product_ndc": [
     "61703-350",
     "61703-408"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAMUSCULAR",
     "INTRAVENOUS",
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "METHOTREXATE SODIUM"
    ],
    "rxcui": [
     "1655956",
     "1946772"
    ],
    "spl_id": [
     "95b8b8da-da4e-4bba-9038-3cf65f3d5c1a",
     "37b3e76b-ac3d-4f93-adf1-91f52f676b8a"
    ],
    "spl_set_id": [
     "0d63ba29-b692-41b4-87e8-351265c8273f",
     "0e30eaef-5a09-4104-8a11-c32933eadeab"
    ],
    "package_ndc": [
     "61703-350-37",
     "61703-350-38",
     "61703-408-41",
     "61703-350-09",
     "61703-350-10",
     "61703-408-25"
    ],
    "unii": [
     "3IG1E710ZN"
    ]
   },
   "update_date": "08/07/2026",
   "therapeutic_category": [
    "Rheumatology",
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)",
   "company_name": "Hospira, Inc., a Pfizer Company",
   "status": "Current"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "03/13/2023",
   "package_ndc": "61703-408-25",
   "generic_name": "Methotrexate Sodium Injection",
   "contact_info": "844-646-4398",
   "availability": "Available",
   "openfda": {
    "application_number": [
     "NDA011719"
    ],
    "brand_name": [
     "METHOTREXATE"
    ],
    "generic_name": [
     "METHOTREXATE"
    ],
    "manufacturer_name": [
     "Hospira, Inc."
    ],
    "product_ndc": [
     "61703-408",
     "61703-350"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAMUSCULAR",
     "INTRATHECAL",
     "INTRAVENOUS",
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "METHOTREXATE SODIUM"
    ],
    "rxcui": [
     "1655956",
     "1946772"
    ],
    "spl_id": [
     "95b8b8da-da4e-4bba-9038-3cf65f3d5c1a",
     "37b3e76b-ac3d-4f93-adf1-91f52f676b8a"
    ],
    "spl_set_id": [
     "0d63ba29-b692-41b4-87e8-351265c8273f",
     "0e30eaef-5a09-4104-8a11-c32933eadeab"
    ],
    "package_ndc": [
     "61703-350-37",
     "61703-350-38",
     "61703-408-41",
     "61703-350-09",
     "61703-350-10",
     "61703-408-25"
    ],
    "unii": [
     "3IG1E710ZN"
    ]
   },
   "update_date": "08/07/2026",
   "therapeutic_category": [
    "Rheumatology",
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)",
   "company_name": "Hospira, Inc., a Pfizer Company",
   "status": "Current"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "03/13/2023",
   "package_ndc": "63323-123-10",
   "generic_name": "Methotrexate Sodium Injection",
   "contact_info": "888-386-1300",
   "availability": "Available",
   "related_info": "Check wholesaler for inventory",
   "openfda": {
    "application_number": [
     "ANDA040263"
    ],
    "brand_name": [
     "METHOTREXATE"
    ],
    "generic_name": [
     "METHOTREXATE SODIUM"
    ],
    "manufacturer_name": [
     "Fresenius Kabi USA, LLC"
    ],
    "product_ndc": [
     "63323-123"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRA-ARTERIAL",
     "INTRAMUSCULAR",
     "INTRAVENOUS"
    ],
    "substance_name": [
     "METHOTREXATE SODIUM"
    ],
    "rxcui": [
     "1946772"
    ],
    "spl_id": [
     "880c2caa-1b11-45ce-a54e-a3733da367f0"
    ],
    "spl_set_id": [
     "b585f621-f6c9-4735-ab61-bd1b401f3df0"
    ],
    "package_ndc": [
     "63323-123-10"
    ],
    "unii": [
     "3IG1E710ZN"
    ]
   },
   "update_date": "08/04/2026",
   "therapeutic_category": [
    "Rheumatology",
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)",
   "company_name": "Fresenius Kabi USA, LLC",
   "status": "Current"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "03/13/2023",
   "package_ndc": "16729-277-35",
   "generic_name": "Methotrexate Sodium Injection",
   "contact_info": "866-941-7875, option 2",
   "availability": "Available",
   "openfda": {
    "application_number": [
     "ANDA040716"
    ],
    "brand_name": [
     "METHOTREXATE"
    ],
    "generic_name": [
     "METHOTREXATE"
    ],
    "manufacturer_name": [
     "Accord Healthcare, Inc."
    ],
    "product_ndc": [
     "16729-277"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRA-ARTERIAL",
     "INTRAMUSCULAR",
     "INTRATHECAL",
     "INTRAVENOUS"
    ],
    "substance_name": [
     "METHOTREXATE"
    ],
    "rxcui": [
     "1655956",
     "1655959",
     "1655960"
    ],
    "spl_id": [
     "2bae3cfe-7aa0-c14c-e063-6294a90a19f4"
    ],
    "spl_set_id": [
     "dd035a9f-cd40-4314-b9d8-2294b8a924e2"
    ],
    "package_ndc": [
     "16729-277-30",
     "16729-277-03",
     "16729-277-35"
    ],
    "nui": [
     "N0000175584",
     "N0000000111"
    ],
    "pharm_class_epc": [
     "Folate Analog Metabolic Inhibitor [EPC]"
    ],
    "pharm_class_moa": [
     "Folic Acid Metabolism Inhibitors [MoA]"
    ],
    "unii": [
     "YL5FZ2Y5U1"
    ]
   },
   "update_date": "08/17/2026",
   "therapeutic_category": [
    "Rheumatology",
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)",
   "company_name": "Accord Healthcare Inc.",
   "status": "Current"
  },
  {
   "update_type": "Reverified",
   "initial_posting_date": "03/13/2023",
   "package_ndc": "61703-124-40",
   "generic_name": "Methotrexate Sodium Injection",
   "contact_info": "844-646-4398",
   "availability": "Available",
   "openfda": {
    "application_number": [
     "NDA011719"
    ],
    "brand_name": [
     "METHOTREXATE"
    ],
    "generic_name": [
     "METHOTREXATE"
    ],
    "manufacturer_name": [
     "Hospira, Inc."
    ],
    "product_ndc": [
     "61703-124",
     "61703-161"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRAMUSCULAR",
     "INTRATHECAL",
     "INTRAVENOUS",
     "SUBCUTANEOUS"
    ],
    "substance_name": [
     "METHOTREXATE SODIUM"
    ],
    "rxcui": [
     "1655956",
     "1946772"
    ],
    "spl_id": [
     "6bb8643f-6ab4-4e1c-bcf9-b82e8cf18910"
    ],
    "spl_set_id": [
     "bd287e89-32f9-4396-95fa-4b562869f476"
    ],
    "package_ndc": [
     "61703-124-40",
     "61703-161-02",
     "61703-161-05"
    ],
    "unii": [
     "3IG1E710ZN"
    ]
   },
   "update_date": "08/07/2026",
   "therapeutic_category": [
    "Rheumatology",
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)",
   "company_name": "Hospira, Inc., a Pfizer Company",
   "status": "Current"
  },
  {
   "update_type": "Revised",
   "initial_posting_date": "03/13/2023",
   "package_ndc": "0703-3675-01",
   "generic_name": "Methotrexate Sodium Injection",
   "contact_info": "800-545-8800",
   "availability": "Unavailable",
   "related_info": "Estimated recovery: December 2026",
   "openfda": {
    "application_number": [
     "ANDA040843"
    ],
    "brand_name": [
     "METHOTREXATE"
    ],
    "generic_name": [
     "METHOTREXATE"
    ],
    "manufacturer_name": [
     "Teva Parenteral Medicines, Inc."
    ],
    "product_ndc": [
     "0703-3675",
     "0703-3671",
     "0703-3678"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRA-ARTERIAL",
     "INTRAMUSCULAR",
     "INTRATHECAL",
     "INTRAVENOUS"
    ],
    "substance_name": [
     "METHOTREXATE SODIUM"
    ],
    "rxcui": [
     "1655956",
     "1655959",
     "1655960"
    ],
    "spl_id": [
     "e81074cc-12b4-4ac9-a5bb-749188989b2c"
    ],
    "spl_set_id": [
     "346ec9ce-dc98-4a55-b55e-d3af11f2d703"
    ],
    "package_ndc": [
     "0703-3671-01",
     "0703-3675-01",
     "0703-3678-01"
    ],
    "unii": [
     "3IG1E710ZN"
    ]
   },
   "update_date": "08/17/2026",
   "therapeutic_category": [
    "Rheumatology",
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)",
   "company_name": "Teva Pharmaceuticals USA, Inc.",
   "shortage_reason": "Other",
   "status": "Current"
  },
  {
   "update_type": "Revised",
   "initial_posting_date": "03/13/2023",
   "package_ndc": "0143-9830-01",
   "generic_name": "Methotrexate Sodium Injection",
   "contact_info": "800-631-2174",
   "availability": "Unavailable",
   "related_info": "Additional lots will be available in the September 2026 timeframe.  Product will be made available as it is released.",
   "openfda": {
    "application_number": [
     "ANDA040632"
    ],
    "brand_name": [
     "METHOTREXATE"
    ],
    "generic_name": [
     "METHOTREXATE"
    ],
    "manufacturer_name": [
     "Hikma Pharmaceuticals USA Inc."
    ],
    "product_ndc": [
     "0143-9830"
    ],
    "product_type": [
     "HUMAN PRESCRIPTION DRUG"
    ],
    "route": [
     "INTRA-ARTERIAL",
     "INTRAMUSCULAR",
     "INTRATHECAL",
     "INTRAVENOUS"
    ],
    "substance_name": [
     "METHOTREXATE"
    ],
    "rxcui": [
     "311625"
    ],
    "spl_id": [
     "49eb25b2-c59c-4374-a216-076767fe1126"
    ],
    "spl_set_id": [
     "b080eb92-fc72-4ce6-a7ab-3f9ce2415526"
    ],
    "package_ndc": [
     "0143-9830-01"
    ],
    "nui": [
     "N0000175584",
     "N0000000111"
    ],
    "pharm_class_epc": [
     "Folate Analog Metabolic Inhibitor [EPC]"
    ],
    "pharm_class_moa": [
     "Folic Acid Metabolism Inhibitors [MoA]"
    ],
    "unii": [
     "YL5FZ2Y5U1"
    ]
   },
   "update_date": "08/13/2026",
   "therapeutic_category": [
    "Rheumatology",
    "Oncology"
   ],
   "dosage_form": "Injection",
   "presentation": "Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)",
   "company_name": "Hikma Pharmaceuticals USA, Inc.",
   "shortage_reason": "Demand increase for the drug",
   "status": "Current"
  }
 ]
}